

Survey finds new NSAID meets or exceeds expectations

Cataract surgeons impressed with bromfenac's efficacy and ease of use for patients

Publish date: Nov 15, 2005 By: Cheryl Guttman

Ophthalmology Times Email | Print | Share | Save | License



Los Angeles—Results from the Xibrom First Experience (XFE) trial show that the new twice-a-day nonsteroidal anti-inflammatory drug (NSAID) is being well received by cataract surgeons and their patients alike, said David F. Chang, MD.

Bromfenac ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals) was approved in March 2005 for the reduction of ocular inflammation after cataract surgery and was launched in June.

David F. Chang, MD E-mail: decye@gearthlink.net Dr. Chang has no financial interest in bromfenac or ISTA Pharmaceuticals. Bromfenac is manufactured for ISTA Pharmaceuticals by Bausch & Lomb under license from Senju Pharmaceutical Co. Ltd. However, more than 400 high-volume cataract surgeons were contacted prior to the launch about participating in an "early experience trial," and more than 90% agreed to use the new agent and report their impressions.

During May and June, those physicians treated a minimum of 10 patients with bromfenac and were asked to rate a variety of product attributes with respect to whether bromfenac performed better or worse than they expected. An interim report based on responses from 225 physicians and 2,604 patient experiences showed that nearly every surgeon was satisfied with the clinical

efficacy and safety of the product and its convenience for their patients. In addition, based on their early positive experience, the respondents were all willing to continue using bromfenac, while a sizable proportion indicated they might make bromfenac their NSAID of choice for cataract surgery.

Convenient dosing

"[Bromfenac] . . . offers potent anti-inflammatory activity for controlling pain and inflammation and also has two features that distinguish it from previously available NSAIDs," said Dr. Chang, clinical professor of ophthalmology, University of California, San Francisco. "Bromfenac is the only topical NSAID to provide the convenience of twice-daily dosing, and it seems to be associated with less incidence of stinging upon instillation.

"Its safety and efficacy were established in placebo-controlled, FDA-monitored clinical trials," Dr. Chang continued. "However, in the absence of head-to-head comparison studies, cataract surgeons are still interested in learning how well bromfenac performs relative to existing NSAIDs before they change their prescribing patterns.

"The XFE study is an opinion survey, not a prospective clinical trial, and the judgments of the participants are based on a very small sample size," he added. "However, the respondents were all experienced cataract surgeons who were very familiar with the clinical performance of existing NSAIDs. Their positive feedback may give other clinicians greater confidence in trying bromfenac."

The physician participants were asked to rate how well bromfenac performed in the following areas:

- Control of inflammation.
- · Ease of use by patients.



POPULAR ARTICLES

Weight-based dosing: Extended-release minocycline efficient, predictable

FDA warns Allergan on Aczone promotion

Exit Accutane: Derms' reactions mixed as Roche pulls long-standing remedy

Gaining control: Birth control pills, spironolactone first-line treatments for hormonal acne

Getting to the root: Look below the surface for cause of hyperandrogenetic symptoms

MORE POPULAR ARTICLES

More	Jot

SPONSORED MEDIA

OTLA Video Player

Multimedia: Why Patients Considering an IUC May Say YES to ParaGard


sponsored multimediaPromiseb A non steroidal topical cream for managing seborrheic dermatitis

MORE MEDIA

- Patient compliance.
- Comfort upon instillation.
- Overall safety profile.
- Patient satisfaction.

Responses were chosen from one of the following four descriptors: exceeded expectations (very satisfied); met expectations (satisfied); met some expectations (dissatisfied); or did not meet expectations (very dissatisfied).

For all categories, the surgeons were nearly unanimous (99% to 100%) in reporting that bromfenac met or exceeded their expectations. For none of the categories were there any responses received indicating that bromfenac had not met physicians' expectations, while across the various categories, 45% to 79% of respondents indicated bromfenac had exceeded their expectations (Figure 1). The two categories associated with the highest rates of "exceeded expectations" responses were ease of use by patients (79%) and patient compliance (69%).



"If a clinician is already happy with ketorolac or diclofenac, it is important that any new NSAID perform at least as well," Dr. Chang said. "The fact that bromfenac so often exceeded physician expectations is a promising indicator that surgeons may eventually find it to be superior to their current preferred NSAID."

Based on their first experiences, 40% of the surgeons indicated they may replace other NSAIDs in their practices with bromfenac, while 57% agreed that they were satisfied and would continue using the new NSAID.



POST A COMMENT

Please complete the form below to Bold = Required	, ,				
Email Address	Your e	Your email address will NOT be published. appears with your comment			
Display Name	appear				
City					
State					
Country					
Remember me: 🔍 Yes 🍭 No					
Comment	Comment read our privacy policy				
Note: does not support HTML All comments submitted are subject to rev	iew, and may be delaye	ed before posting. We reserve the right not to post comments.			
All comments submitted are subject to rev	iew, and may be delaye	ed before posting. We reserve the right not to post comments.			
All comments submitted are subject to rev		LATEST DRUG NEWS			
All comments submitted are subject to rev		LATEST DRUG NEWS			
All comments submitted are subject to rev	ve Total Joint	LATEST DRUG NEWS Cetuximab Linked to Resection of Liver Metastases			
All comments submitted are subject to rev Submit Now >> LATEST PRACTICE NEWS Rural Residents More Likely to Hav Replacement Jninsured Show Higher Risk for De	ve Total Joint eath Following	LATEST DRUG NEWS Cetuximab Linked to Resection of Liver Metastases H1N1 Influenza Rates Drop in Many States			

Response

Adults

the Hospital

SNS: Web Surfing Linked to Brain Function in Older

Survey finds new NSAID meets or exceeds expectations - Cataract surg ...



Allergy & Immunology	Health Care Information	eNewsletters	
Alzheimer's Disease	Technology	Patient Education Center	
Asthma	Practice Management	Blogs	
BPH	Business Operations	Discussions	
Breast Cancer	Human Resources	ModernMedicine Radio	
Cardiology	Health Law & Policy	Sundication	

ModernMedicine Bringing together Advanstar's trusted healthcare journals along with powerful tools, resource, decision support and advisory functions



Acne

Home | About Us | ModernMedicine Team | Editorial and Advertising Policy | Our Publications | Terms & Conditions | Contact Us | Medical News | Medical Articles | CME Center | Patient Education | Practice Management | All Content | Privacy Policy | Terms of Use | Linking and RSS Policy

© 2009 Advanstar Communications, Inc. All rights reserved.

Reproduction in whole or in part is prohibited. Please send any technical comments or questions to our webmaster.